K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer.
Nuvalent Inc. has described RAC-α serine/threonine-protein kinase (AKT1; PKBα) E17K mutant inhibitors reported to be useful for the treatment of cancer.
Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer.
Researchers from Stony Brook University Renaissance School of Medicine recently disclosed the design and development of a novel, multitargeted miRNA approach based on a gemcitabine-modified microRNA (miR)-129 mimic (Gem-miR-129) to overcome resistance to EGFR inhibitors.
Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer.
Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter.
A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).
KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases.
Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.
RSS
